|By Marketwired .||
|March 10, 2014 07:00 AM EDT||
ST. PAUL, MN -- (Marketwired) -- 03/10/14 -- EnteroMedics Inc. (NASDAQ: ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the U.S. Food and Drug Administration's Office of Device Evaluation has rescheduled a meeting of the Center for Devices and Radiologic Health's (CDRH) Advisory Committee for Tuesday, June 17, 2014 to review the Maestro® System delivering VBLOC® vagal blocking therapy as a treatment for morbid obesity. The prior meeting date presented a significant scheduling conflict for the CDRH.
About EnteroMedics Inc.
EnteroMedics is a medical device company focused on the development and commercialization of its neuroscience based technology to treat obesity and metabolic diseases. EnteroMedics' proprietary technology, VBLOC® vagal blocking therapy, delivered by a pacemaker-like device called the Maestro® Rechargeable System, is designed to intermittently block the vagus nerves using high-frequency, low-energy, electrical impulses. VBLOC allows people with obesity to take a positive path towards weight loss, addressing the lifelong challenge of obesity and its comorbidities without sacrificing wellbeing or comfort. EnteroMedics' Maestro Rechargeable System has received CE Mark and is listed on the Australian Register of Therapeutic Goods.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements about EnteroMedics Inc. Our actual results could differ materially from those discussed due to known and unknown risks, uncertainties and other factors including our limited history of operations; our losses since inception and for the foreseeable future; our lack of commercial regulatory approval for our Maestro® System for the treatment of obesity in the United States or in any foreign market other than Australia and the European Community; our preliminary findings from our EMPOWER and ReCharge pivotal studies; our ability to comply with the Nasdaq continued listing requirements; our ability to commercialize our Maestro System; our dependence on third parties to initiate and perform our clinical studies; the need to obtain regulatory approval for any modifications to our Maestro System; physician adoption of our Maestro System and VBLOC® vagal blocking therapy; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in the annual report on Form 10-K filed March 7, 2013. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.
Caution - Investigational device. Limited by Federal (United States) law to investigational use.
The implantation procedure and usage of the Maestro® System carry some risks, such as the risks generally associated with laparoscopic procedures and those related to treatment as described in the ReCharge clinical study informed consent.
Greg S. Lea
Containers are changing the security landscape for software development and deployment. As with any security solutions, security approaches that work for developers, operations personnel and security professionals is a requirement. In his session at DevOps Summit, Kevin Gilpin, CTO and Co-Founder of Conjur, will discuss various security considerations for container-based infrastructure and related DevOps workflows.
Jul. 2, 2015 06:00 AM EDT Reads: 931
Jul. 1, 2015 07:15 PM EDT Reads: 2,539
Jul. 1, 2015 05:00 PM EDT Reads: 903
Jul. 1, 2015 05:00 PM EDT Reads: 2,235
Jul. 1, 2015 04:09 PM EDT Reads: 671
Jul. 1, 2015 03:30 PM EDT Reads: 1,090
Jul. 1, 2015 03:00 PM EDT Reads: 1,962
Jul. 1, 2015 02:45 PM EDT Reads: 1,102
Jul. 1, 2015 02:30 PM EDT Reads: 1,212
Jul. 1, 2015 02:21 PM EDT Reads: 694
Jul. 1, 2015 01:15 PM EDT Reads: 2,182
Jul. 1, 2015 12:54 PM EDT Reads: 656
Jul. 1, 2015 12:15 PM EDT Reads: 2,065
Jul. 1, 2015 12:00 PM EDT Reads: 2,024
Jul. 1, 2015 11:45 AM EDT Reads: 1,053